Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions
Multiple sclerosis (MS) is a complex, chronic immune-mediated disease characterized by acute and progressive inflammatory damage of the central nervous system. MS manifests clinically with unpredictable neurological symptoms from focal inflammatory attacks as well as gradual neurodegeneration which...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Neurotherapeutics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1878747925000662 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399323377270784 |
|---|---|
| author | Gauruv Bose Simon D.X. Thebault Giulia Fadda John A. Brooks Mark S. Freedman |
| author_facet | Gauruv Bose Simon D.X. Thebault Giulia Fadda John A. Brooks Mark S. Freedman |
| author_sort | Gauruv Bose |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is a complex, chronic immune-mediated disease characterized by acute and progressive inflammatory damage of the central nervous system. MS manifests clinically with unpredictable neurological symptoms from focal inflammatory attacks as well as gradual neurodegeneration which contribute significantly to long-term disability progression. As treatment options advance, developing more personalized strategies capture heterogeneous mechanisms of injury which may be targeted or predict outcomes has been a focus of ongoing investigation. The role of soluble biomarkers has emerged as a pivotal tool to assist in these goals. Early promising candidates include neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP); these intermediate filaments that are expressed in neurons and astrocytes, respectively, are reliably measurable from blood samples and can reveal clinical and subclinical changes, as well as predict progression. Changes in these biomarkers can indicate a response to therapy, thus potentially be used as endpoints in clinical trials. Furthermore, recent research has identified a potential role of these and other soluble biomarkers in other neuroimmunological conditions including neuromyelitis spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein associated disease (MOGAD), autoimmune encephalitis, neurosarcoidosis, neuropsychiatric involvement in connective tissue disorders and vasculitides, and a host of neurodegenerative conditions. By integrating biomarker analysis into routine clinical assessments, healthcare providers may move toward a more nuanced and individualized care model, better equipped to meet the challenges posed by these multifaceted diseases. Understanding the dynamics of these biomarkers has many applications that can improve personalized medicine in MS. |
| format | Article |
| id | doaj-art-e5f9f3488da64de3bd44804fd83f8642 |
| institution | Kabale University |
| issn | 1878-7479 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurotherapeutics |
| spelling | doaj-art-e5f9f3488da64de3bd44804fd83f86422025-08-20T03:38:22ZengElsevierNeurotherapeutics1878-74792025-07-01224e0058810.1016/j.neurot.2025.e00588Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditionsGauruv Bose0Simon D.X. Thebault1Giulia Fadda2John A. Brooks3Mark S. Freedman4Department of Medicine, The University of Ottawa and Ottawa Hospital Research Institute, Canada; Corresponding author.Department of Medicine, The University of Ottawa and Ottawa Hospital Research Institute, Canada; Department of Neurology and Neurosurgery, Montreal Neurological Institute and McGill University Health Centre, CanadaDepartment of Medicine, The University of Ottawa and Ottawa Hospital Research Institute, CanadaDepartment of Medicine, The University of Ottawa and Ottawa Hospital Research Institute, CanadaDepartment of Medicine, The University of Ottawa and Ottawa Hospital Research Institute, CanadaMultiple sclerosis (MS) is a complex, chronic immune-mediated disease characterized by acute and progressive inflammatory damage of the central nervous system. MS manifests clinically with unpredictable neurological symptoms from focal inflammatory attacks as well as gradual neurodegeneration which contribute significantly to long-term disability progression. As treatment options advance, developing more personalized strategies capture heterogeneous mechanisms of injury which may be targeted or predict outcomes has been a focus of ongoing investigation. The role of soluble biomarkers has emerged as a pivotal tool to assist in these goals. Early promising candidates include neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP); these intermediate filaments that are expressed in neurons and astrocytes, respectively, are reliably measurable from blood samples and can reveal clinical and subclinical changes, as well as predict progression. Changes in these biomarkers can indicate a response to therapy, thus potentially be used as endpoints in clinical trials. Furthermore, recent research has identified a potential role of these and other soluble biomarkers in other neuroimmunological conditions including neuromyelitis spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein associated disease (MOGAD), autoimmune encephalitis, neurosarcoidosis, neuropsychiatric involvement in connective tissue disorders and vasculitides, and a host of neurodegenerative conditions. By integrating biomarker analysis into routine clinical assessments, healthcare providers may move toward a more nuanced and individualized care model, better equipped to meet the challenges posed by these multifaceted diseases. Understanding the dynamics of these biomarkers has many applications that can improve personalized medicine in MS.http://www.sciencedirect.com/science/article/pii/S1878747925000662Multiple sclerosisBiomarkersNeuroinflammationNeurofilamentPredictionDiagnosis |
| spellingShingle | Gauruv Bose Simon D.X. Thebault Giulia Fadda John A. Brooks Mark S. Freedman Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions Neurotherapeutics Multiple sclerosis Biomarkers Neuroinflammation Neurofilament Prediction Diagnosis |
| title | Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions |
| title_full | Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions |
| title_fullStr | Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions |
| title_full_unstemmed | Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions |
| title_short | Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions |
| title_sort | role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions |
| topic | Multiple sclerosis Biomarkers Neuroinflammation Neurofilament Prediction Diagnosis |
| url | http://www.sciencedirect.com/science/article/pii/S1878747925000662 |
| work_keys_str_mv | AT gauruvbose roleofsolublebiomarkersintreatingmultiplesclerosisandneuroinflammatoryconditions AT simondxthebault roleofsolublebiomarkersintreatingmultiplesclerosisandneuroinflammatoryconditions AT giuliafadda roleofsolublebiomarkersintreatingmultiplesclerosisandneuroinflammatoryconditions AT johnabrooks roleofsolublebiomarkersintreatingmultiplesclerosisandneuroinflammatoryconditions AT marksfreedman roleofsolublebiomarkersintreatingmultiplesclerosisandneuroinflammatoryconditions |